Vicarious Surgical CEO Adam Sachs sells 3,342 in stock - Investing.com
| RBOT Stock | USD 9.25 0.38 4.28% |
Slightly above 55% of Vicarious Surgical's private investors are presently thinking to get in. The analysis of overall sentiment of trading Vicarious Surgical stock suggests that some investors are interested at this time. Vicarious Surgical's investing sentiment can be driven by a variety of factors including economic data, Vicarious Surgical's earnings reports, geopolitical events, and overall market trends.
Vicarious | Build AI portfolio with Vicarious Stock |
Vicarious Surgical CEO Adam Sachs sells 3,342 in stock Investing.com
Read at news.google.com
 |
Vicarious Surgical Fundamental Analysis
We analyze Vicarious Surgical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vicarious Surgical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vicarious Surgical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Vicarious Surgical is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Vicarious Surgical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vicarious Surgical stock to make a market-neutral strategy. Peer analysis of Vicarious Surgical could also be used in its relative valuation, which is a method of valuing Vicarious Surgical by comparing valuation metrics with similar companies.
Peers
Vicarious Surgical Related Equities
| OFIX | Orthofix Medical | 13.46 | ||||
| RGTI | Rigetti Computing | 11.61 | ||||
| LUNG | Pulmonx Corp | 0.61 | ||||
| PRCT | Procept Biorobotics | 0.72 | ||||
| HUMA | Humacyte | 0.88 | ||||
| MXCT | MaxCyte | 0.96 | ||||
| QTRX | Quanterix Corp | 1.32 | ||||
| QSI | QuantumSi | 1.37 | ||||
| INDI | Indie Semiconductor | 4.46 |
Additional Tools for Vicarious Stock Analysis
When running Vicarious Surgical's price analysis, check to measure Vicarious Surgical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicarious Surgical is operating at the current time. Most of Vicarious Surgical's value examination focuses on studying past and present price action to predict the probability of Vicarious Surgical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicarious Surgical's price. Additionally, you may evaluate how the addition of Vicarious Surgical to your portfolios can decrease your overall portfolio volatility.